Southport Capital Management’s ADMA Biologics ADMA Stock Holding History

Southport Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$21K	Buy	+11,500	New	+$17.9K	0.01%	219

Other funds holding ADMA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Southport Capital Management's ADMA Position: Q1 2022 in Review

Southport Capital Management opened a new position in ADMA Biologics (ADMA) in Q1 2022: 11,500 shares worth $21K. The stake represents 0.01% of the portfolio and ranks #219 among its holdings.

105 funds tracked by Wall St. Rank hold ADMA as of Q1 2022.

Southport Capital Management held 11,500 shares of ADMA Biologics worth $21K as of Q1 2022.
ADMA Biologics was a new Southport Capital Management position in Q1 2022.
ADMA Biologics made up 0.01% of Southport Capital Management's portfolio in Q1 2022, its #219 holding.
105 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2022.

Based on Southport Capital Management's 13F filing for Q1 2022, filed 25 Apr 2022.